Barclays Maintains Overweight on Collegium Pharmaceutical, Lowers Price Target to $41
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $48 to $41.
Last updated: 2026-11-19 07:59:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Collegium Pharmaceutical, Inc. (COLL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $25.94, with a market capitalization of $793.98M and a P/E ratio of 20.80. Over the past 52 weeks, its price has ranged from $21.43 to $50.79. This page covers its latest market performance, valuation, price trends and company information.
$793.98M | |
$25.36 | |
$26.25 | |
$24.57 | |
$25.55 | |
394.77K | |
762.23K | |
20.80 | |
$50.79 | |
$21.43 | |
-- | |
2026-09-30 |
Collegium Pharmaceutical, Inc. (COLL) last closed at $25.94 as of 2026-11-19 00:31:00, up 1.57% ($0.40) from the previous close of $25.55.
During the latest regular trading session, COLL traded between $24.57 and $26.25, with a volume of 394.77K shares. The closing price was near the upper end and near the lower end of its 52-week range.
Over the past seven days, Collegium Pharmaceutical, Inc. (COLL) moved from $24.47 to $25.94, representing a gain of 6.02% ($1.47).
The stock traded between $23.99 and $26.25 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 511.76 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 15.4%
COLL is currently trading at $25.94, placing it 15.4% of the way from its 52-week low of $21.43 to its 52-week high of $50.79. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 423 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Collegium Pharmaceutical, Inc. and COLL stock.
Barclays analyst Glen Santangelo maintains Collegium Pharmaceutical (NASDAQ:COLL) with a Overweight and lowers the price target from $48 to $41.
Liquidia Corporation (LQDA) reported strong Q3 2026 results with earnings of 80 cents per share and revenues of $225.3 million, driven by Yutrepia sales of $222.7 million. However, a $389.7 million litigation settlement with United Therapeutics restricts Yutrepia's promotion to pulmonary arterial hypertension only, eliminating PH-ILD commercialization. The company maintains confidence in PAH growth and has sufficient cash reserves to support settlement payments and pipeline expansion.
Mirum Pharmaceuticals announced positive results from the Phase III AZURE-4 study for brelovitug, an investigational treatment for chronic hepatitis delta virus (HDV). The drug met its primary endpoint with 59% and 44% response rates across two dosing regimens versus 0% for delayed treatment. Combined with positive AZURE-1 data, these two studies will support a U.S. BLA filing in the first half of 2027, with potential commercial launch expected in Q4 2027.
Eligible investors can buy real shares of Collegium Pharmaceutical, Inc. (COLL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to COLL, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between COLL shares and USD.
COLL Shares to USD
1.00 COLL shares = 25.942 USD
Calculations are estimates based on the latest available price and are for reference only.